A nonprofit drug manufacturer is moving forward with plans to stem the rising tide of insulin costs in the US.
Utah-based Civica has selected German-based research organization Profil as its human clinical trial partner to support the development of Civica’s affordable insulins. Civica is planning to produce three insulin biosimilars – dubbed glargine, lispro and aspart – each of which will be available both in vials and pre-filled pens.
Civica has plans to sell the insulins at significantly lower prices than what is currently available on the market, although the House recently passed a President Joe Biden-backed cap on insulin prices at $35 per month. The Senate has yet to vote on the bill.
“The need for affordable insulin is urgent, especially for uninsured and underinsured populations. With its extensive experience and…
Click here to view original post